Description
An adenosine A2B receptor antagonist (Ki = 0.553 nM); selective for adenosine A2B over A1, A2A, and A3 receptors (Kis = >10,000 nM); reduces intracellular calcium concentrations in Jurkat T cells expressing the human A2B receptor (IC50 = 1.13 nM); reduces Zika viral plaque formation (IC50 = 43.8 nM); delays tumor growth and reduces tumor volume and the number of pulmonary metastases in the B16 mouse model of melanoma at 0.25 µg/head, i.p.,
Formal name: 8-[4-[[4-(4-chlorophenyl)-1-piperazinyl]sulfonyl]phenyl]-3,9-dihydro-1-propyl-1H-purine-2,6-dione
Synonyms:
Molecular weight: 529
CAS: 1092351-10-4
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Antivirals||Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Research Area|Cancer|Cell Migration & Metastasis||Research Area|Immunology & Inflammation|Adaptive Immunity||Research Area|Infectious Disease|Viral Diseases|Zika